OPEN ACCESS
J. M. Kane et al. / Open Journal of Psychiatry 2 (2012) 423-432 431
[13] Haro, J.M., Edgell, E.T., Jones, P.B., et al. (2003) The
European Schizophrenia Outpatient Health Outcomes
(SOHO) study: Rationale, methods and recruitment. Acta
Psychiatrica Scandinavica, 107, 222-232.
doi:10.1034/j.1600-0447.2003.00064.x
[14] De Hert, M., et al. (2010) The METEOR study of diabe-
tes and other metabolic disorders in patients with schizo-
phrenia treated with antipsychotic drugs. I. Methodology.
International Journal of Methods in Psychiatric Research,
19, 195-210. doi:10.1002/mpr.322
[15] Thomas, S.H.L., Drici, M.D., Hall, G.C., et al. (2010)
Safety of sertindole versus risperidone in schizophrenia:
Principal results of the sertindole cohort prospective
study (SCoP). Acta Psychiatrica Scandinavica, 122. 345-
355. d oi:10.1111/j.1600-0447.2010.01563.x
[16] Furedi, J., Mohr, P., Swingler, D., et al. (2006) Psychiatry
in selected countries of Central and Eastern Europe: An
overview of the current situation. Acta Psychiatrica
Scandinavica, 114, 223-231.
doi:10.1111/j.1600-0447.2006.00804.x
[17] Kosnar, K. (2003) Mentally ill patients in central Europe
being kept in padlocked, caged beds. British Medical
Journal, 327, 1249. doi:10.1136/bmj.327.7426.1249-c
[18] Polubinskaya, S.V. (2000) Reform in psychiatry in post-
Soviet countries. Acta Psychiatrica Scandinavica, 101,
106-108.
doi:10.1111/j.0902-4441.2000.007s020[dash]24.x
[19] Rybakowski, J.K. (2004) Academic psychiatry in Poland:
Adjustment to rapid changes. Molecular Psychiatry, 9,
813-815. doi:10.1038/sj.mp.4001569
[20] Tomov, T. (2001) Mental health reforms in Eastern
Europe. Acta Psychiatrica Scandinavica, 104, 21-26.
doi:10.1034/j.1600-0447.2001.1040s2021.x
[21] Brown, S., Birtwistle, J., Roe, L. et al. (1999) The un-
healthy lifestyle of people with schizophrenia. Psycho-
logical Medicine, 29, 697-701.
doi:10.1017/S0033291798008186
[22] Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey,
D.H. (2005) Schizophrenia and increased risks of cardio-
vascular disease. American Heart Journal, 150, 1115-
1121. doi:10.1016/j.ahj.2005.02.007
[23] Strassnig, M., Brar, J.S., Ganguli, R. (2003) Nutritional
assessment of patients with schizophrenia: A preliminary
study. Schizophrenia Bulletin, 29, 393-397.
doi:10.1093/oxfordjournals.schbul.a007013
[24] Auquier, P., Lancon, C., Rouillon, F., Lader, M. (2007)
Mortality in schizophrenia. Pharmacoepidemiol Drug
Safety, 16, 1308-1312. doi:10.1002/pds.1496
[25] Osby, U., Correia, N., Brandt, L. et al. (2000) Mortality
and causes of death in schizophrenia in Stockholm
County, Sweden. Schizophrenia Research, 45, 21-28.
doi:10.1016/S0920-9964(99)00191-7
[26] Saha, S., Chant, D., McGrath, J. (2007) A systematic
review of mortality in schizophrenia: is the differential
mortality gap worsening? Archives of General Psychiatry,
64, 1123-1131. doi:10.1001/archpsyc.64.10.1123
[27] The World Health Organization (WHO) (2009) Global
health risks: Mortality and burden of disease attributable
to selected major risks. WHO Press, Geneva.
http://www.who.int/healthinfo/global-burden-disease/Glo
balHealthRisks/report/full.pdf
[28] McEvoy, J.P., Meyer, J.M., Goff, D.C., et al. (2005)
Prevalence of the metabolic syndrome in patients with
schizophrenia: baseline results from the Clinical Antip-
sychotic Trials of Intervention Effectiveness (CATIE)
schizophrenia trial and comparison with national esti-
mates from NHANES III. Schizophrenia Research, 80,
19-32. doi:10.1016/j.schres.2005.07.014
[29] Newcomer, J.W. (2007) Metabolic syndrome and mental
illness. American Journal of Managed Care, 13, S170-
S177.
[30] American Diabetes Association (ADA), American Psy-
chiatric Association, American Association of Clinical
Endocrinologists and The North American Association
for the Study of Obesity (2004) Consensus development
on antipsychotic drugs and obesity and diabetes. Diabetes
Care, 27, 51-59.
[31] Lieberman, J.A., Stroup, T.S., McEvoy, J.P., et al. (for
the Clinical Antipsychotic Trials of Intervention Effec-
tiveness (CATIE) investigators) (2005) Effectiveness of
antipsychotic drugs in patients with chronic schizophre-
nia. The New England Journal of Medicine, 353, 1209-
1223. doi:10.1056/NEJMoa051688
[32] Newcomer, J.W. (2005) Second-generation (atypical)
antipsychotics and metabolic side-effects: A comprehen-
sive literature review. CNS Drugs, 19, 1-93.
[33] Rummel-Kluge, C., Komossa, K., Schwarz, S., et al.
(2010) Head-to-head comparisons of metabolic side ef-
fects of second generation antipsychotics in the treatment
of schizophrenia: a systematic review and meta-analysis.
Schizophrenia Research, 123, 225-233.
[34] Papageorgiou, G. (2011) Country differences in patient
characteristics and treatment in schizophrenia: Data from
a physician-based survey in Europe. European Psychiatry,
26, 17-28. doi:10.1016/S0924-9338(11)71710-2
[35] Leitao-Azevedo, C.L., de Abreu, M.G.B., Guimaraes,
L.R., et al. (2006) Overweight and obesity in schizo-
phrenic patients taking clozapine compared to the use of
other antipsychotics. Revista de Psiquiatria do Rio
Grande do Sul, 28, 120-128.
[36] Hsiao, C.-C., Ree, S.-C., Chang, Y.-L., et al. (2004) Obe-
sity in schizophrenic outpatients receiving antipsychotics
in Taiwan. Psychiatry and Clinical Neurosciences, 58,
403-409. d oi:10.1111/j.1440-1819.2004.01275.x
[37] Hung, C.-F. (2005) Diabetes mellitus in patients with
schizophrenia in Taiwan. Progress in Neuro-Psychophar-
macology and Biological Psychiatry, 28, 523-527.
doi:10.1016/j.pnpbp.2005.01.003
[38] Campbell, T.C. and Chen, J.S. (1994) Chronic degenera-
tive diseases: Perspectives from China. The American
Journal of Clinical Nutrition, 56, S1153-S1173.
[39] Hirota, T., Mara, M., Ohguri, M., et al. (1992) Effect of
diet and lifestyle on bone mass in Asian young women.
The American Journal of Clinical Nutrition, 55, 1168-
1173.
[40] Chien, I.-C., Hsu, J.H., Lin, C.H., et al. (2009) Preva-
lence of diabetes in patients with schizophrenia in Taiwan:
Copyright © 2012 SciRes. OPEN ACCESS
J. M. Kane et al. / Open Journal of Psychiatry 2 (2012) 423-432
Copyright © 2012 SciRes.
432
OPEN ACCESS
A population-based National Health Insurance study.
Schizophrenia Research, 111, 17-22.
[41] Ferreira, L. (2010) A case-control study of cardiovascular
risk factors and cardiovascular risk among patients with
schizophrenia in a country in the low cardiovascular risk
regions of Europe. Revista Portuguesa de Cardiologia,
29, 1481-1493.
[42] De Leon, J. and Diaz, F.J. (2005) A meta-analysis of
worldwide studies demonstrates an association between
schizophrenia and tobacco smoking behaviors. Schizo-
phrenia Research, 76, 135-157.
doi:10.1016/j.schres.2005.02.010
[43] McClave, A.K., McKnight-Eily, L.R., Davis, S.P. and
Dube, S.R. (2010) Smoking characteristics of adults with
selected lifetime mental illnesses: results from the 2007
national health interview survey. American Journal of
Public Health, 100, 2464-2472.
doi:10.2105/AJPH.2009.188136
[44] Ciara, K. and McCreadis, R. (2000) Cigarette smoking
and schizophrenia. Advances in Psychiatric Treatment, 6,
327-331.
[45] Kuman, V. and Postma, P. (2005) Nicotine use in schizo-
phrenia: The self-medication hypothesis. Neuroscience &
Biobehavioral Reviews, 29, 1021-1034.
doi:10.1016/j.neubiorev.2005.02.006
[46] Lavin, M.R., Sinis, S.G. and Mason, S.E. (1996) What is
the clinical importance of cigarette smoking in schizo-
phrenia? American Journal on Addictions, 5, 189-208.
[47] Mobascher, A. and Winterer, G. (2008) The molecular
and cellular neurobiology of nicotine abuse in schizo-
phrenia. Pharmacopsychiatry, 41, S51-S59.
doi:10.1055/s-2008-1081463
[48] Scottish Schizophrenia Research Group (2000) Smoking
habits and plasma lipid peroxide and vitamin E levels in
never-treated first-episode patients with schizophrenia:
Preliminary report. The British Journal of Psychiatry, 176,
290-293.
[49] Baker, A., Richmond, R. and Haile, M. (2006) A ran-
domized controlled trial of a smoking cessation interven-
tion among people with a psychiatric disorder. American
Journal of Psychiatry, 163, 1934-1942.
doi:10.1176/appi.ajp.163.11.1934
[50] Chaves, L. and Shirakawa, I. (2008) Nicotine use in pa-
tients with schizophrenia evaluated by the Fagerström
Tolerance Questionnaire: A descriptive analysis from a
Brazilian sample. Revista Brasileira de Psiquiatria, 30,
350-352. doi:10.1590/S1516-44462008005000014
[51] De Leon, J., Dadvard, M., Canuso, C. et al. (1995)
Schizophrenia and smoking: an epidemiological survey in
a state hospital. American Journal of Psychiatry, 152,
453-455.
[52] Liao, D.-L., Yang, J.-Y., Lee, S.-M., et al. (2002) Smok-
ing in Chronic Schizophrenic Inpatients in Taiwan. Neu-
ropsychobiology, 45, 172-175.
doi:10.1159/000063666
[53] Herran, A., de Santiago, A., Sandoya, M., et al. (2004)
Determinants of smoking behavior in outpatients with
schizophrenia. Schizophrenia Bulletin, 41, 373-381.
[54] Hughes, J.R., Hatsukami, D.K., Mitchell, J.E., et al.
(1986) Prevalence of smoking among psychiatric outpa-
tients. American Journal of Psychiatry, 143, 993-997.
[55] Gu, D., Kelly, T.N., Wu, X. et al. (2009) Mortality attrib-
utable to smoking in China. The New England Journal of
Medicine, 360, 150-159. doi:10.1056/NEJMsa0802902
[56] Nakanishi, N, Takatorigi, T. and Suzuki, K. (2005) Ciga-
rette smoking and the risk of metabolic syndrome in mid-
dle-aged Japanese male office workers. Industrial Health,
43, 295-301. doi:10.2486/indhealth.43.295
[57] Oh, S.W., Yoon, Y.S., Lee, E.S. et al. (2005) Association
between cigarette smoking and metabolic syndrome.
Diabetes Care, 28, 2064-2066.
doi:10.2337/diacare.28.8.2064
[58] Kelly, D.L., McMahon, R.P., Wehring, H.J. et al. (2011)
Cigarette smoking and mortality risk in people with
schizophrenia. Schizophrenia Bulletin, 37, 832-838.
doi:10.1093/schbul/sbp152
[59] Dalack, G.W., Healy, D.J. and Meador-Woodruff, J.H.
(1998) Nicotine dependence in schizophrenia: Clinical
phenomena and laboratory findings. American Journal of
Psychiatry, 155, 1490-1501.
[60] Mortensen, P.B. and Juel, K. (1993) Mortality and causes
of death in first-admitted schizophrenic patients. The
British Journal of Psychiatry, 163, 183-189.
[61] Folsom, D. (2009) Improving physical health care for
subjects with serious mental illness. In: Meyer, J.M. and
Nasrallah, H.A., Eds., Medical Illness and Schizophrenia,
2nd Edition, American Psychiatric Publishing, Washing-
ton DC, London, 3-15.
[62] Kuehn, B.M. (2010) Questionable antipsychotic pre-
scribing remains common, despite serious risks. The
Journal of the American Medical Association, 303, 1582-
1584. doi:10.1001/jama.2010.453
[63] Morrato, E.H., Druss, B., Hartung, D.M. et al. (2010)
Metabolic testing rates in 3 state medicaid programs after
FDA warnings and ADA/APA recommendations for
second-generation antipsychotic drugs. Archives of Gen-
eral Psychiatry, 67, 17-24.
doi:10.1001/archgenpsychiatry.2009.179
[64] Brenner, S. and Cohen, C.I. (2009) Medical health in
aging persons with schizophrenia. In: Meyer, J.M., Nas-
rallah, H.A. (Eds.), Medical Illness and Schizophrenia,
2nd Edition American Psychiatric Publishing, Washing-
ton D.C. and London, pp. 377-413 at 391.
[65] Brown, S., Inskip, H. and Barraclough, B. (2000) Causes
of the excess mortality of schizophrenia. British Journal
of Psychiatry, 177, 212-217. doi:10.1192/bjp.177.3.212
[66] Bae, S.-W. and Brekke, J.S. (2002) Characteristics of
Korean-Americans with schizophrenia: A cross-ethnic
comparison with African-Americans, Latinos, and Euro-
Americans. Schizophrenia Bulletin, 28, 703-717.
doi:10.1093/oxfordjournals.schbul.a006974
[67] Goater, N., King, M., Cole, E., et al. (1999) Ethnicity and
Outcomes of psychosis. British Journal of Psychiatry,
175, 34-42. doi:10.1192/bjp.175.1.34